Infliximab Biosimilar - Anti-TNF-alpha mAb - Research Grade
Source
DrugBank DB00065
Species
Human
Expression system
Mammalian
Molecular weight
144kDa
Purity
>85%
Buffer
PBS pH7.5
Delivery condition
Blue ice (+4°C)
Delivery lead time in business days
3-5 days if in stock; 3-5 weeks if production needed
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
Infliximab,Infliximab,TNF-alpha,anti-TNF-alpha
Reference
PX-TA1009
Note
For research use only. Not suitable for human use.
Isotype
IgG1
Clonality
Monoclonal Antibody
Description of Infliximab Biosimilar - Anti-TNF-alpha mAb - Research Grade
General information about Infliximab
Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases. This includes Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease. It is given by slow injection into a vein, typically at six- to eight-week intervals. Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are monoclonal antibodies and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a “chimeric monoclonal antibody”. This product is for research use only.
SPR results for Infliximab Biosimilar - Anti-TNF-alpha mAb and Human TNFa/TNF-alpha
Human TNFa Recombinant Protein (cat. No. PX-P3058) and Infliximab Biosimilar - Anti-TNF-alpha mAb (cat. No. PX-TA1009) were injected in OpenSPR giving a KD of 3.26E-09.
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Infliximab Biosimilar – Anti-TNF-alpha mAb – Research Grade” Cancel reply
Reviews
There are no reviews yet.